Five Minutes with Matthew Walls of EpiStem
This article was originally published in Clinica
Executive Summary
Matthew Walls joined biotechnology firm Epistem as CEO in February 2007. The Manchester, UK-based firm focuses on stem cell technologies for use in therapeutic and biomarker applications. Before joining EpiStem, Mr Walls headed data management firm Oxford BioSignals, and has also worked for chemical company ICI and pharmaceutical giant AstraZeneca